There are 2789 resources available
1051P - Impacts of skeletal muscle on survival in resected stage III malignant melanoma
Presenter: Susie Youn
Session: ePoster Display
1052P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: ePoster Display
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
981P - Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Presenter: Sarwan Bishnoi
Session: ePoster Display
982P - A phase II study of SHR-1701 plus famitinib for patients with previously treated advanced pancreatic cancer or biliary tract cancer
Presenter: jing xie
Session: ePoster Display
983P - Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
Presenter: Nuria Kotecki
Session: ePoster Display
984P - Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
Presenter: Capucine Baldini
Session: ePoster Display
985P - Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors
Presenter: Thorsten Goetze
Session: ePoster Display
986P - Antitumor effect of zolbetuximab combined with chemotherapeutic agents or an anti-mPD-1 antibody in syngeneic immune-competent mice
Presenter: Toshihide Nishibata
Session: ePoster Display
987P - A new therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy
Presenter: toshifumi obonai
Session: ePoster Display